NEW DATA ON USE OF PEGASYS FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
June 20, 2013
Past MPN Research Foundation grantees Srdan Verstovsek and Ross Levine contributed to a paper recently published by the American Society of Hematology which reports on a study of PV and ET patients treated with pegylated interferon alpha-2a, commonly known as Pegasys. Click here for the abstract and to read the full study.
Pegasys is a treatment that some MPN patients have found useful, though it is not always covered by insurance. For a history of how the Foundation has assisted patients with getting this medication covered click here.
Join our community to get the latest research, patient stories, and exclusive content delivered right to your inbox. Plus, when you subscribe, receive the latest NCCN guidelines and resources to support your journey.